Company
Neuren Pharmaceuticals Ltd
ASX:NEU
Neuren Pharmaceuticals Ltd (ASX:NEU) is developing two new drug therapies to treat multiple serious neurological disorders that emerge in early childhood.
32 stories
Neuren Pharmaceuticals receives EC Orphan designations for drug candidate NNZ-2591
The company is developing new therapies to treat serious neurological disorders that emerge in early childhood, none of which have any approved medicines, and is advancing development of its second drug candidate NNZ-2591 for Phelan-McDermi
Neuren Pharmaceuticals secures Rare Pediatric Disease designation for trofinetide to treat Rett Syndrome
Trofinetide is an investigational drug developed by Neuren designed to treat the core symptoms of Rett syndrome by potentially reducing neuroinflammation and supporting synaptic function.
Neuren Pharmaceuticals gets green light for a patent in the U.S.
The method has demonstrated efficacy in pre-clinical models of Parkinson’s disease and stroke.
Neuren Pharmaceuticals bags A$11.5M to progress Rett syndrome trials
Placement anchored by A$10 million from UK fund Lanstead Capital.
Neuren Pharmaceuticals drug shows promise in treating Rett syndrome
Clinical improvement of 15% to 16% from baseline was observed.
Neuren Pharmaceuticals granted ASX trading halt pending trial update
The halt will remain in place until Wednesday 22nd March 2017.